|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Heart, Lung, and Blood Institute (NHLBI) Thalassemia Clinical Research Network |
|---|---|
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00000623 |
Purpose
The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
| Condition | Intervention |
|---|---|
|
Anemia, Cooley's Beta-Thalassemia Hematologic Diseases Thalassemia Osteoporosis Iron Overload Hypertension, Pulmonary |
Drug: Deferoxamine Drug: Deferiprone Drug: Arginine Drug: Sildenafil Drug: Decitabine |
| Study Type: | Observational |
| Study Design: | Prospective |
| Official Title: | Thalassemia Clinical Research Network (TCRN) |
| Estimated Enrollment: | 1000 |
| Study Start Date: | July 2000 |
| Study Completion Date: | July 2006 |
Show Detailed Description Eligibility| Ages Eligible for Study: | 1 Year to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Please refer to specific studies for eligibility criteria.
Contacts and Locations| United States, California | |
| Children's Hospital Oakland | |
| Oakland, California, United States, 94609 | |
| United States, Massachusetts | |
| Children's Hospital | |
| Boston, Massachusetts, United States, 02115 | |
| United States, New York | |
| Weill Medical College of Cornell University | |
| New York, New York, United States, 10021 | |
| United States, Pennsylvania | |
| Children's Hospital of Philadelphia | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Canada, Ontario | |
| Toronto General Hospital | |
| Toronto, Ontario, Canada, M5G 2C4 | |
| Principal Investigator: | Alan R. Cohen, MD | Children's Hospital of Philadelphia |
| Principal Investigator: | Patricia J. Giardina, MD | Weill Medical College of Cornell University |
| Principal Investigator: | Ellis J. Neufeld, MD, PhD | Children's Hospital |
| Principal Investigator: | Nancy F. Olivieri, MD | Toronto General Hospital |
| Principal Investigator: | Elliott P. Vichinsky, MD | Children's Hospital & Research Center Oakland |
| Principal Investigator: | Sonja McKinlay, PhD | New England Research Institutes, Inc. |
More Information
| Study ID Numbers: | 317, U01 HL65232, U01 HL65233, U01 HL65238, U01 HL65239, U01 HL65244, U01 HL65260 |
| Study First Received: | October 27, 1999 |
| Last Updated: | November 29, 2007 |
| ClinicalTrials.gov Identifier: | NCT00000623 |
| Health Authority: | United States: Federal Government |
|
chelator iron transfusion anemia thalassemia |
|
Deferiprone Iron Metabolism Disorders Bone Diseases Respiratory Tract Diseases Musculoskeletal Diseases Hemoglobinopathy Deferoxamine Metabolic Diseases Hematologic Diseases Beta-thalassemia Vascular Diseases Anemia Anemia, Hemolytic Osteoporosis Sildenafil |
Bone Diseases, Metabolic Decitabine Thalassemia Anemia, Hemolytic, Congenital Thalassemia minor Genetic Diseases, Inborn Hypertension, Pulmonary Hemoglobinopathies Beta-Thalassemia Lung Diseases Iron Overload Metabolic disorder Iron Hypertension |
|
Antimetabolites Vasodilator Agents Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Iron Chelating Agents Enzyme Inhibitors |
Cardiovascular Agents Pharmacologic Actions Siderophores Phosphodiesterase Inhibitors Therapeutic Uses Cardiovascular Diseases Chelating Agents |
